Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE23.4800
- TODAY'S CHANGE (%)0.9100 (4.0319%)
- Bid / Lots23.0200/ 1
- Ask / Lots23.7500/ 1
- Open / Previous Close23.0300 / 22.5700
- Day Range
- 52 Week Range
- Volume718,726
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 13287 | 22.89 |
| 09:36 ET | 2705 | 22.83 |
| 09:38 ET | 2349 | 22.96 |
| 09:39 ET | 1205 | 23.01 |
| 09:41 ET | 3919 | 23.295 |
| 09:43 ET | 450 | 23.305 |
| 09:45 ET | 4550 | 23.21 |
| 09:48 ET | 1777 | 23.13 |
| 09:50 ET | 8871 | 23.33 |
| 09:52 ET | 4893 | 23.25 |
| 09:54 ET | 999 | 23.23 |
| 09:56 ET | 600 | 23.22 |
| 09:57 ET | 1250 | 23.09 |
| 09:59 ET | 2400 | 23.11 |
| 10:01 ET | 2700 | 23.34 |
| 10:03 ET | 3912 | 23.1301 |
| 10:06 ET | 1800 | 23.19 |
| 10:08 ET | 2184 | 23.24 |
| 10:10 ET | 1500 | 23.27 |
| 10:12 ET | 4426 | 23.35 |
| 10:14 ET | 2216 | 23.43 |
| 10:15 ET | 3904 | 23.57 |
| 10:17 ET | 3389 | 23.66 |
| 10:19 ET | 3235 | 23.76 |
| 10:21 ET | 5597 | 23.79 |
| 10:24 ET | 6473 | 23.8 |
| 10:26 ET | 3900 | 23.86 |
| 10:28 ET | 5277 | 23.8 |
| 10:30 ET | 2308 | 23.71 |
| 10:32 ET | 5803 | 23.8 |
| 10:33 ET | 1200 | 23.81 |
| 10:35 ET | 3593 | 23.85 |
| 10:37 ET | 4120 | 23.59 |
| 10:39 ET | 5845 | 23.61 |
| 10:42 ET | 3538 | 23.51 |
| 10:44 ET | 4418 | 23.51 |
| 10:46 ET | 5003 | 23.54 |
| 10:48 ET | 12868 | 23.59 |
| 10:50 ET | 6895 | 23.63 |
| 10:51 ET | 5400 | 23.74 |
| 10:53 ET | 10978 | 23.78 |
| 10:55 ET | 19356 | 23.745 |
| 10:57 ET | 18601 | 23.64 |
| 11:00 ET | 14170 | 23.62 |
| 11:02 ET | 9999 | 23.66 |
| 11:04 ET | 6800 | 23.69 |
| 11:06 ET | 4057 | 23.73 |
| 11:08 ET | 7594 | 23.69 |
| 11:09 ET | 8408 | 23.74 |
| 11:11 ET | 6064 | 23.77 |
| 11:13 ET | 9876 | 23.76 |
| 11:15 ET | 4398 | 23.85 |
| 11:18 ET | 10223 | 23.67 |
| 11:20 ET | 3099 | 23.595 |
| 11:22 ET | 1400 | 23.64 |
| 11:24 ET | 1762 | 23.72 |
| 11:26 ET | 2800 | 23.685 |
| 11:27 ET | 3198 | 23.69 |
| 11:29 ET | 341 | 23.66 |
| 11:31 ET | 2688 | 23.59 |
| 11:33 ET | 12082 | 23.52 |
| 11:36 ET | 2355 | 23.57 |
| 11:38 ET | 900 | 23.56 |
| 11:40 ET | 2327 | 23.54 |
| 11:42 ET | 3379 | 23.56 |
| 11:44 ET | 2847 | 23.565 |
| 11:45 ET | 4209 | 23.56 |
| 11:47 ET | 1975 | 23.55 |
| 11:49 ET | 3700 | 23.52 |
| 11:51 ET | 1000 | 23.53 |
| 11:54 ET | 2222 | 23.58 |
| 11:56 ET | 400 | 23.59 |
| 11:58 ET | 2900 | 23.595 |
| 12:00 ET | 1403 | 23.54 |
| 12:02 ET | 600 | 23.46 |
| 12:03 ET | 2723 | 23.47 |
| 12:05 ET | 3138 | 23.55 |
| 12:07 ET | 1700 | 23.56 |
| 12:09 ET | 900 | 23.56 |
| 12:12 ET | 700 | 23.64 |
| 12:14 ET | 2900 | 23.615 |
| 12:16 ET | 400 | 23.625 |
| 12:18 ET | 5935 | 23.545 |
| 12:20 ET | 300 | 23.54 |
| 12:21 ET | 2448 | 23.55 |
| 12:23 ET | 4568 | 23.545 |
| 12:25 ET | 5153 | 23.57 |
| 12:27 ET | 1900 | 23.55 |
| 12:30 ET | 5665 | 23.55 |
| 12:32 ET | 1688 | 23.61 |
| 12:34 ET | 5754 | 23.6 |
| 12:36 ET | 2688 | 23.6 |
| 12:38 ET | 2394 | 23.61 |
| 12:39 ET | 1710 | 23.61 |
| 12:41 ET | 1000 | 23.6 |
| 12:43 ET | 2403 | 23.56 |
| 12:45 ET | 1920 | 23.51 |
| 12:48 ET | 6147 | 23.58 |
| 12:50 ET | 3514 | 23.59 |
| 12:52 ET | 3552 | 23.605 |
| 12:54 ET | 3111 | 23.65 |
| 12:56 ET | 7047 | 23.55 |
| 12:57 ET | 11546 | 23.52 |
| 12:59 ET | 27406 | 23.48 |
Jun 26, 2024
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD), from 6:30AM ET on Wednesday Jun 26, 2024 by Dow Jones
6:30AM ET on Wednesday Jun 26, 2024 by Dow Jones
Jun 14, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 1.9B | -13.5x | --- |
Catalyst Pharmaceuticals Inc | 1.9B | 28.4x | --- |
Veracyte Inc | 1.6B | -23.0x | --- |
Galapagos NV | 1.7B | 49.7x | --- |
Maravai LifeSciences Holdings Inc | 1.7B | -7.0x | --- |
Genmab A/S | 16.4B | 21.1x | +22.71% |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Director
- John Evans
- Chief Financial Officer, Treasurer
- Terry-Ann Burrell
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
|---|---|
Revenue (TTM) | $360.9M |
Shares Outstanding | 82.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.87 |
EPS | $-1.74 |
Book Value | $12.02 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -50.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
